Waiting
Login processing...

Trial ends in Request Full Access Tell Your Colleague About Jove
Journal / Cancer Research / Analyser för validering av Histone…
JoVE Journal
Cancer Research

A subscription to JoVE is required to view this content.

JoVE Journal Cancer Research
Analyser för validering av Histone Acetyltransferas hämmare
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
Journal (Cancer Research)
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
Invasive Behavior of Human Breast Cancer Cells in Embryonic Zebrafish
Journal (Cancer Research)
Invasive Behavior of Human Breast Cancer Cells in Embryonic Zebrafish
 
Click here for the English version

Analyser för validering av Histone Acetyltransferas hämmare

Article DOI: 10.3791/61289-v • 09:11 min • August 6th, 2020
August 6th, 2020 •
1, 1
1Department of Anatomy and Cell Biology, and UF Health Cancer Center, University of Florida College of Medicine

Chapters

Summary
Automatic Translation

Please note that all translations are automatically generated.

Click here for the English version.

Hämmare av histonacetyltransferaser (HATs, även känd som lysinacetyltransferaser), såsom CBP/p300, är potentiella therapeutics för behandling av cancer. Men, rigorösa metoder för att validera dessa hämmare behövs. Tre in vitro-metoder för validering inkluderar HAT-analyser med rekombinanta acetyltransferaser, immunoblotting för histonacetylation i cellodling, och ChIP-qPCR.

Tags

Cancerforskning lysinacetyltransferaser KATs CBP/p300 hitonacetyltransfashämmare screeningmetoder histonacetylation epigenetik cancer genreglering
Read Article

Get cutting-edge science videos from JoVE sent straight to your inbox every month.

Waiting X
Simple Hit Counter